CD27 and prostate cancer: Using C4-2B prostate cancer cells expressing PSCA, we next tested the cytotoxic activity of the 8t28Z CAR in comparison to two variations where the costimulatory domain was replaced with either a CD27- or 4-1BB–derived moiety (8t27Z and 8tBBZ, respectively).